Zymeworks Inc. (ZYME) Dividend History

Company News

• Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

  Zymeworks, a clinical-stage biotechnology company, will report its Q2 2025 financial results on August 7, 2025, and participate in upcoming investor conferences. The company has received regulatory approvals for zanidatamab, a HER2-targeted bispecific antibody for biliary tract cancer treatment.

  GlobeNewswire Inc.

  Featured Companies: JAZZ
• Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

  The oncology industry has seen significant progress, with cancer deaths falling by 33% in the last 30 years. Several key players, including Oncolytics Biotech, Novartis, Lantheus Holdings, Sutro Biopharma, and Zymeworks, have reported promising developments in their cancer research and treatments.

  Benzinga

  Featured Companies: LNTH ONCY STRO
• Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

  Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: VNDA
• Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

  Zymeworks has a strong financial position, with a robust liquidity position and a cash runway that extends into 2027. Learn why ZYME stock is a Buy.

  Seeking Alpha

  Featured Companies: JAZZ
• 2 Biotech Stocks That Could Make You Richer

  These biotech companies are seeing a spike in revenue growth.

  The Motley Fool

  Featured Companies: VYGR